Calcipotriene/Betamethasone Foam (Enstilar) for Psoriasis
Calcipotriene/Betamethasone Foam (Enstilar) for Psoriasis
April 11, 2016 (Issue: 1492)
The FDA has approved Enstilar (Leo), an aerosol
foam formulation of the synthetic vitamin D3 analog
calcipotriene and the high-potency corticosteroid
betamethasone dipropionate, for topical treatment
of plaque psoriasis in adults. Topical...more
- PL McCormack. Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp. Drugs 2011; 71:709.
- A Mason et al. Topical treatments for chronic plaque psoriasis: an abridged Cochrane systematic review. J Am Acad Dermatol 2013; 69:799.
- Drugs for psoriasis. Med Lett Drugs Ther 2015; 57:81.
- L Hollesen Basse et al. Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle. J Invest Dermatol 2014; 134 (suppl 2): S33, abstract 192.
- C Leonardi et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris – a randomized phase III study (PSO-FAST). J Drugs Dermatol 2015; 14:1468.
- M Lebwohl et al. A novel aerosol foam formulation of calcipotriene (Cal) 0.005% plus betamethasone dipropionate (BD) 0.064% is more efficacious than Cal and BD foam alone in treating psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase II study. Presented at the 73rd Annual Meeting of the American Academy of Dermatology, San Francisco, March 20-24, 2015. Abstract 1670. Available at: www.aad.org. Accessed March 31, 2016.
- J Koo et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – a randomized phase II study. J Dermatolog Treat 2016; 27:120.
- V Taraska et al. A novel aerosol foam formulation of calcipotriol and betamethasone has no impact on HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris. J Cutan Med Surg 2016: 20:44.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Calcipotriene/Betamethasone Foam (Enstilar) for Psoriasis
Article code: 1492c
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
